VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31

VITASPRING BIOMEDICAL CO. LTD.

Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 17, 2026

$0.03+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $6.58M
P/E (TTM): –
Dividend yield: –

VITASPRING BIOMEDICAL CO. LTD. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-01-31	FY 2025 2025-01-31	FY 2024 2024-01-31	FY 2023 2023-01-31	FY 2022 2022-01-31	FY 2021 2021-01-31	FY 2020 2020-01-31	FY 2019 2019-01-31	FY 2018 2018-01-31	FY 2017 2017-01-31
Revenue	0	0	0	0	5.61	0.25	0.02	0.02	0.02	0
Cost of Revenue	0	0	0	3.33	3.55	0.14	0.01	0.00	0.00	0
Gross Profit	0	0	0	-3.33	2.07	0.11	0.00	0.01	0.01	0
Selling, General & Admin	0.39	0.68	1.12	0.84	0.94	0.54	0.02	0.04	–	–
General & Administrative	–	–	–	0.84	0.94	0.54	0.02	0.04	0.02	0.00
Operating Expenses	–	–	–	–	–	–	–	-0.04	-0.02	0.00
Total Costs & Expenses	–	–	–	–	–	0	–	–	–	–
Operating Income	-0.39	-0.68	-1.12	-4.18	1.13	0.43	0.01	-0.02	-0.01	–
Income from Equity Investments	–	–	–	–	–	-0.43	0.01	-0.02	–	–
Other Non-Operating Income	–	–	0	0.01	0	0	0.01	0	–	–
Asset Impairment Charges	–	0	0.01	0	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	0	0.00	0	–	–
Pretax Income	-0.39	-0.68	-1.12	-4.17	1.13	-0.43	0.01	-0.02	–	–
Income Tax Expense	0.03	0.10	0	-0.01	0.22	0	0	0	–	–
Income from Continuing Operations	–	–	–	-0.08	0.22	–	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	-0.43	-0.02	–	–	–
Net Income incl. Noncontrolling Interests	–	-0.77	-1.12	-4.16	0.91	–	–	–	-0.01	0.00
Net Income	-0.42	-0.77	-1.12	-4.16	0.91	0.43	0.01	-0.02	-0.01	0.00
Net Income to Common	–	–	–	–	–	–	–	-0.02	–	–
EPS (Basic)(per share)	–	–	–	–	–	0.00	0.00	0.00	0.00	0.00
EPS (Diluted)(per share)	0.00	0.00	-0.01	-0.02	0.00	0.00	0.00	0.00	0.00	0.00
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	206	91	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	207	207	207	207	206	91	11	9.82	2.29	0.05
EBITDA	–	-0.67	-1.10	–	–	–	–	–	–	–
Net Investment Income	–	–	–	–	-1.26	0.43	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: 9.8%

Financial strength

Current ratio: 0.01
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –